Home/Pipeline/Beta-Hydroxybutyrate 21FS

Beta-Hydroxybutyrate 21FS

Diagnosis and monitoring of Diabetic Ketoacidosis (DKA)

DevelopmentActive

Key Facts

Indication
Diagnosis and monitoring of Diabetic Ketoacidosis (DKA)
Phase
Development
Status
Active
Company

About Vidan Diagnostics

Vidan Diagnostics is an early-stage, private diagnostics company targeting the urgent need for improved Diabetic Ketoacidosis (DKA) management. Its core asset is the Beta-Hydroxybutyrate 21FS test, which measures blood levels of beta-hydroxybutyrate (BHB), the primary ketone body in DKA, offering a more specific and reliable diagnostic marker than traditional methods. The company is likely in a pre-revenue, development stage, aiming to commercialize a product that could enable faster diagnosis, better treatment guidance, and reduced healthcare costs in emergency and point-of-care settings. Success will depend on securing regulatory clearance, demonstrating clinical utility, and navigating a competitive landscape with established and emerging ketone testing solutions.

View full company profile